Lumos Diagnostics Raises $63M AUD in ASX IPO

July 8, 2021

Lumos has been admitted to the Australian Securities Exchange (ASX) with trading commencing on July 5, 2021 after raising $63 million AUD in an Initial Public Offering (IPO).

May 5, 2021

Lumos Diagnostics Appoints Three Industry Leaders as Independent Directors

Lumos Diagnostics announced today the expansion of its board with the appointment of three new independent directors to support the continued growth of the company’s rapid point-of-care diagnostic products and services business.

March 3, 2021

Lumos Diagnostics Announces Northern Diagnostics as Official Canadian Distribution Partner

Lumos Diagnostics announces a distribution partnership with Northern Diagnostics to bring the rapid FebriDx® test into Canada to facilitate the accurate diagnosis of viral and bacterial infections at the point of care.

November 18, 2020

Lumos Diagnostics Partners with WHO and CDC for Antibiotic Awareness Week from November 18-24

From November 18-24, Lumos Diagnostics and partners of WHO’s World Antimicrobial Awareness Week and CDC’s Antibiotic Awareness Week will share what clinicians and patients need to know about antibiotics and the importance of using antibiotics wisely in both community and healthcare settings.

September 17, 2020

New Study Highlights the Utility of the FebriDx® Test for Rapid Triage and Identification of COVID-19

Lumos Diagnostics today announced the publication of a COVID-19 (SARS-CoV-2) clinical trial in The International Journal of Clinical Practice. Kettering General Hospital in the UK prospectively performed a clinical assessment of the FebriDx® point-of-care (POC) fingerstick blood test to rapidly assess and differentiate viral from bacterial symptomatic respiratory infections. The study concluded that FebriDx could be deployed as part of a reliable triage strategy for identifying symptomatic cases as possible COVID-19 in the pandemic.

September 8, 2020

FebriDx® Test Featured in UK National Institute for Health and Care Excellence (NICE) Medtech Innovation Briefing (MIB)

Lumos Diagnostics rapid point-of-care (POC) FebriDx® test was featured in a Medtech Innovation Briefing (MIB), as part of the United Kingdom’s National Institute for Health and Care Excellence (NICE) guidance for the COVID-19 pandemic response. This MIB addresses the impact that the FebriDx test can have on the concurrent COVID-19 pandemic and antimicrobial resistance global health crises.

July 27, 2020

New Study Suggests FebriDx® as a ‘Front Door Triage Tool’ in the Fight Against COVID-19

A new study in the Journal of Infection by Dr. Tristan Clark, et al. titled "Diagnostic accuracy of the FebriDx host response point-of-care test in patients hospitalised with suspected COVID-19" identifies the FebriDx® test as a rapid, highly accurate, and affordable 'front door triage tool' to help healthcare providers differentiate viral from bacterial infection in patients with suspected COVID-19.


Reach out to Lumos today to understand how we can deliver you a customized point-of-care diagnostic solution.